When do the AMOXICILLIN PEDIATRIC patents expire, and when will AMOXICILLIN PEDIATRIC go generic?

Sponsor	Phase
Tejs Ehlers Klug	PHASE4
Danish Cancer Society	PHASE4
Nanjing First Hospital, Nanjing Medical University	PHASE3

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Chartwell Rx	AMOXICILLIN PEDIATRIC	amoxicillin	FOR SUSPENSION;ORAL	061931-003	Dec 1, 1982	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: August 23, 2026

Amoxicillin pediatric is a mature, multi-source generic market with minimal patent protection and limited product-level pricing power. Revenue is driven by prescription volume, seasonal infection patterns, formulation availability, government purchasing and manufacturing reliability rather than innovation. The main commercial products are oral suspensions, chewable tablets and, less frequently, pediatric capsules or dispersible dosage forms.

No publicly reported company discloses standalone revenue for "amoxicillin pediatric." Financial performance must therefore be assessed through U.S. prescription demand, generic pricing, supplier participation, shortages and portfolio economics.

What is the pediatric amoxicillin market?

Pediatric amoxicillin is the child-focused segment of the broader amoxicillin market. It is used mainly for acute otitis media, streptococcal pharyngitis, sinusitis and selected respiratory or dental infections. The FDA-approved products include oral suspension powders in multiple concentrations, chewable tablets and capsules labeled for pediatric use.

The market has four commercial characteristics:

It is predominantly generic.
Oral suspension is the most operationally important pediatric form.
Demand rises during respiratory-virus and school seasons.
Profitability depends on reliable supply and manufacturing scale.

Amoxicillin is an aminopenicillin and is distinct from amoxicillin-clavulanate. The latter has separate formulation, manufacturing and competitive economics.

Core pediatric dosage forms

Dosage form	Typical commercial role	Principal commercial issue
Powder for oral suspension	Primary pediatric product, especially for younger children	Reconstitution, bottle availability and shortage risk
Chewable tablets	Useful for older children who cannot swallow capsules	Lower flexibility for weight-based dosing
Capsules	More relevant to older children and adolescents	Less suitable for young children
Combination products	Usually amoxicillin-clavulanate, not plain amoxicillin	Separate active ingredient and pricing dynamics

FDA labeling identifies multiple approved concentrations, including 125 mg/5 mL, 200 mg/5 mL, 250 mg/5 mL and 400 mg/5 mL suspensions, depending on the manufacturer and product presentation.[1]

How large is the amoxicillin pediatric market?

A reliable standalone global market size for pediatric amoxicillin is not publicly available. Commercial databases generally aggregate amoxicillin with adult capsules, tablets, injectables or amoxicillin-clavulanate, while public company reports group the product into broader generic portfolios.

The addressable market is nevertheless structurally large because amoxicillin remains a first-line antibiotic in several common pediatric indications. CDC guidance identifies amoxicillin as a preferred treatment for many children with acute otitis media and as a recommended option for group A streptococcal pharyngitis.[2][3]

Demand is concentrated in:

Primary-care pediatrics
Family medicine
Urgent-care clinics
Emergency departments
Retail pharmacies
Public-sector and institutional purchasing

The market is volume-heavy but value-constrained. A prescription for a bottle of suspension typically generates much less revenue than a specialty drug or branded chronic-care product. Manufacturers compete on supply continuity, wholesale discounts and formulary access.

What is the financial trajectory for pediatric amoxicillin?

The likely financial trajectory is stable-to-declining unit economics, offset by episodic volume increases and supply-driven price spikes.

Period	Market condition	Financial effect
Pre-2020	Mature generic supply with routine seasonal demand	Low prices and limited margins
2020-2021	Reduced circulation of many respiratory pathogens	Lower pediatric antibiotic demand
Late 2022-2023	Respiratory illness rebound and reported supply shortages	Higher demand, stock-outs and temporary pricing pressure
2024 onward	Normalized demand with continuing generic competition	Stable volume, structurally low margins

The sharpest recent market disruption occurred during the 2022-2023 respiratory-illness period, when demand for amoxicillin suspension increased and pharmacies reported product shortages. The FDA and American Society of Health-System Pharmacists tracked supply constraints affecting amoxicillin oral suspension products during that period.[4][5]

The shortage episode improved the revenue outlook for manufacturers with available inventory, but it did not create durable branded pricing power. Once supply normalized, competitive generic pricing remained the dominant force.

Revenue exposure by manufacturer

Public manufacturers typically report amoxicillin within broader generic or hospital-product segments. Relevant supplier groups have included large generic companies such as Hikma, Sandoz, Teva and other FDA-approved generic manufacturers, although product availability varies by national market and over time.

Company type	Revenue exposure	Margin profile
Large diversified generic manufacturer	Small contribution within broad portfolio	Protected by scale and purchasing leverage
Regional generic supplier	Potentially meaningful during shortages	Higher supply and customer-concentration risk
Contract manufacturer	Manufacturing revenue rather than branded product revenue	Dependent on agreements and plant utilization
Retail pharmacy or wholesaler	Distribution margin	Sensitive to reimbursement and inventory availability

A manufacturer with a broad pediatric antibiotic portfolio can capture cross-selling benefits through amoxicillin, amoxicillin-clavulanate, azithromycin and cefdinir. Plain amoxicillin alone is unlikely to materially affect the financial results of a large diversified pharmaceutical company.

When does pediatric amoxicillin lose exclusivity?

Pediatric amoxicillin has already lost market exclusivity. The original U.S. amoxicillin products were approved decades ago, and generic competition has existed for many years.

Exclusivity category	Current position
New chemical entity exclusivity	Expired
Orphan-drug exclusivity	Not applicable
Pediatric exclusivity	No current market exclusivity
New formulation exclusivity	No broad exclusivity covering standard pediatric suspension
Generic competition	Established
Biosimilar exclusivity	Not applicable

The Hatch-Waxman pathway permits abbreviated new drug applications for generic amoxicillin because the active ingredient is well established and the relevant reference products are long approved.[6]

What patents protect pediatric amoxicillin?

No commercially important, active U.S. patent estate appears to protect the basic pediatric amoxicillin molecule or standard oral suspension products. The principal composition-of-matter patents expired long ago.

Patent protection by product element

Product element	Patent position
Amoxicillin active ingredient	Historical patents expired
Standard oral suspension	No broad active exclusivity comparable to a branded new drug
Chewable tablet	Generic formulation competition established
Powder reconstitution process	Potential process know-how, but generally not market exclusivity
Flavoring and excipients	Usually nonexclusive formulation choices
Bottle and measuring device	May be protected by ordinary commercial or design rights, not core drug exclusivity
Manufacturing process	Possible confidential know-how and process controls, but not a broad barrier to generic entry

The FDA Orange Book lists patents and exclusivity associated with approved drug products. Standard generic amoxicillin products generally do not have a patent barrier that prevents additional abbreviated applications.[7]

Patent risk can still arise from a specific delivery system, flavoring system, packaging configuration or combination product. Such rights would be narrower than a patent covering plain amoxicillin pediatric therapy and would not ordinarily prevent competition across the entire market.

What is the Orange Book status of pediatric amoxicillin?

The Orange Book status is that of a mature generic product category with multiple reference-listed and therapeutically equivalent products. The relevant regulatory pathway is ANDA approval or, for some products, an older abbreviated or full NDA history.

The main Orange Book commercial implications are:

Multiple manufacturers can compete once FDA requirements are met.
Therapeutic-equivalence listings support pharmacy substitution where state law and payer rules permit.
There is no meaningful branded patent listing comparable to products in protected therapeutic classes.
Pediatric suspension products may differ in concentration, flavor, bottle size and reconstitution instructions even when the active ingredient is the same.

The FDA approval decision remains product-specific. A manufacturer must demonstrate pharmaceutical equivalence, bioequivalence where applicable, manufacturing compliance and acceptable stability for the dosage form.[8]

Are there Paragraph IV challenges for pediatric amoxicillin?

Paragraph IV litigation is not a material market driver for standard pediatric amoxicillin. Paragraph IV certifications are most commercially important when a generic applicant challenges an unexpired Orange Book patent covering a branded product.

For plain amoxicillin pediatric suspension, the relevant patents are generally expired or absent from the practical competitive pathway. Generic applicants therefore face ordinary ANDA review and manufacturing requirements rather than a major patent-litigation hurdle.

Potential disputes may still involve:

A branded reformulation
A novel flavor or dosing system
A combination product
A patent covering a specialized delivery device
Manufacturing or trade-secret allegations

These disputes would affect a particular product or applicant, not the entire pediatric amoxicillin category.

What patent litigation affects pediatric amoxicillin?

No major, category-defining patent litigation currently shapes the standard U.S. pediatric amoxicillin market. Litigation exposure is low compared with markets such as GLP-1 therapies, oncology biologics, inhaled medicines or extended-release products.

The more relevant legal risks are commercial and regulatory:

FDA warning letters or manufacturing observations
Product recalls
Failure to meet dissolution, assay or microbiological specifications
Contamination or stability problems
Contract disputes over supply
State-law substitution and reimbursement disputes

For oral suspensions, manufacturing controls are especially important because the product requires powder uniformity, accurate reconstitution, acceptable taste, preservative control where applicable and stability after water is added.

What formulations are protected in pediatric amoxicillin?

The standard pediatric formulations have limited protectable differentiation. Commercial value comes from execution rather than exclusivity.

Oral suspension

The oral suspension is the most important pediatric formulation. Its practical competitive attributes include:

Concentration
Bottle size
Flavor
Reconstitution volume
Shelf life after reconstitution
Storage requirements
Supplied dosing syringe or cup
Ease of shaking and dosing

These characteristics can influence physician, pharmacist and caregiver preference, but they rarely create durable market protection.

Chewable tablets

Chewable tablets can improve adherence for older children. The principal development challenges are taste masking, tablet size, dose flexibility and dose accuracy. Generic competition limits pricing power unless the product has a meaningful delivery or packaging advantage.

Combination formulations

Amoxicillin-clavulanate is commercially more differentiated because it has separate formulation and stability requirements. It should not be treated as a direct financial equivalent of plain amoxicillin pediatric suspension.

What manufacturing and supply barriers affect the market?

Manufacturing and supply reliability are the principal barriers to commercial success.

Key constraints include:

Active pharmaceutical ingredient availability.
Capacity for pediatric liquid manufacturing.
Availability of bottles, caps, labels and dosing devices.
Quality control for microbiological and stability testing.
Adequate inventory before seasonal demand increases.
Dependence on overseas active-ingredient and excipient supply chains.

Pediatric liquid products can be less attractive to manufacturers than solid oral dosage forms because they require more packaging components, more handling and tighter controls after reconstitution. The result is a market where a small number of suppliers may account for a substantial share of available inventory at a particular time, even though many products have regulatory approval.

How does pediatric amoxicillin compare with other pediatric antibiotics?

Product	Generic competition	Typical commercial profile	Supply sensitivity
Amoxicillin suspension	Very high	Low-price, high-volume first-line antibiotic	High during respiratory surges
Amoxicillin-clavulanate suspension	High	Higher value and more complex formulation	Moderate to high
Azithromycin suspension	High	Alternative for selected indications and allergy settings	Moderate
Cefdinir suspension	High	Broader-spectrum option with higher unit value	Moderate
Penicillin V suspension	Generic, narrower use	Lower-volume pediatric product	Variable

Amoxicillin benefits from guideline preference in common infections. Broad-spectrum alternatives can command higher prices per prescription, but antimicrobial-stewardship policies favor amoxicillin where clinically appropriate.[2][3]

What generic launch risks exist?

The main risks are operational rather than patent-related.

Risk	Probability	Commercial impact
Patent blocking standard generic entry	Low	Low
FDA review delay	Moderate	Moderate
Manufacturing inspection or quality failure	Moderate	High
Seasonal demand misforecast	Moderate	High
Price erosion after additional entrants	High	High
Shortage-driven temporary upside	Intermittent	Moderate to high
Reimbursement compression	High	Moderate
Caregiver adherence or taste problems	Moderate	Moderate

A new entrant can obtain market access without a major patent settlement, but it may struggle to secure profitable pharmacy and wholesaler contracts. The market favors manufacturers that can maintain fill rates during peak demand.

What licensing deals affect pediatric amoxicillin?

No major licensing transaction is required to commercialize standard generic amoxicillin pediatric products. The market is based mainly on ANDA ownership, contract manufacturing, supply agreements and distribution arrangements.

Relevant transaction structures include:

Technology transfer for an approved suspension
Contract manufacturing agreements
Private-label supply to pharmacy chains
Government procurement contracts
Regional distribution licenses
Portfolio acquisitions involving multiple generic antibiotics

A licensing deal involving plain amoxicillin would typically have modest strategic value unless it includes manufacturing capacity, an established customer base or a differentiated pediatric delivery system.

What is the geographic coverage of pediatric amoxicillin?

Amoxicillin is marketed widely across North America, Europe, Asia-Pacific and emerging markets. Regulatory and commercial conditions differ by jurisdiction.

In the United States, FDA approval and state substitution rules determine market access. In Europe, national pricing, tendering and centralized procurement can compress prices further. In emerging markets, private retail demand may coexist with government tenders, and product quality, cold-chain requirements where applicable and local manufacturing rules can shape supplier selection.

Geographic expansion is therefore more likely to create incremental volume than premium pricing. Local registration, pharmacopoeial compliance, packaging requirements and reliable distribution remain the main barriers.

What is the outlook for pediatric amoxicillin?

The base-case outlook is stable demand with low unit-price growth and recurring supply volatility. Volume should remain supported by pediatric infections and guideline preference, while revenue per prescription will remain constrained by generic competition.

The strongest financial opportunities are concentrated in:

Reliable suspension supply during seasonal peaks
High-concentration products that reduce bottle volume
Better dosing devices and packaging
Private-label and institutional contracts
Integrated pediatric antibiotic portfolios
Markets with limited local manufacturing capacity

The weakest opportunity is an undifferentiated, low-scale product competing solely on price.

Key Takeaways

Pediatric amoxicillin is a mature generic market with no meaningful composition-of-matter exclusivity.
Oral suspension is the commercially central pediatric formulation.
Product-specific revenue is not publicly disclosed by major manufacturers.
Financial performance depends on volume, supply reliability, seasonal demand and procurement contracts.
Patent, Paragraph IV and biosimilar risks are low.
Manufacturing, packaging and quality compliance are more important barriers than intellectual property.
The 2022-2023 supply disruption created temporary pricing and volume opportunities but did not change the long-term low-margin structure.
Amoxicillin-clavulanate is a separate and generally higher-value market.
A differentiated delivery system or dependable supply position offers more commercial value than another standard generic approval.

FAQs

Is pediatric amoxicillin a branded or generic drug?

It is primarily a generic drug. Multiple manufacturers market pediatric amoxicillin products under generic labels or private-label arrangements.

Does amoxicillin pediatric have biosimilar competition?

No. Amoxicillin is a small-molecule antibiotic, so competition occurs through generic drug applications rather than the biosimilar pathway.

Can a company obtain a patent on a new amoxicillin suspension?

A company may seek patents on a genuinely novel formulation, delivery system, packaging configuration or manufacturing process. Such protection would generally be narrower than a patent on amoxicillin itself.

Why do amoxicillin pediatric shortages occur despite many generic manufacturers?

Approved manufacturers may not all produce continuously. Shortages can result from concentrated liquid-manufacturing capacity, API constraints, packaging shortages, quality events and sudden seasonal demand.

Is amoxicillin pediatric commercially more attractive than amoxicillin-clavulanate?

Usually not on a unit-value basis. Amoxicillin-clavulanate has more complex formulation requirements and generally higher value per prescription, while plain amoxicillin has broader first-line use and simpler generic competition.

References

U.S. Food and Drug Administration. (2023). Amoxicillin prescribing information. FDA Drugs@FDA database.
Centers for Disease Control and Prevention. (2024). Outpatient clinical care for pediatric populations: Acute otitis media. https://www.cdc.gov
Centers for Disease Control and Prevention. (2024). Clinical guidance for group A streptococcal pharyngitis. https://www.cdc.gov
U.S. Food and Drug Administration. (2023). Drug shortages: Amoxicillin oral suspension. FDA Drug Shortages Database. https://www.accessdata.fda.gov
American Society of Health-System Pharmacists. (2023). Drug shortages: Amoxicillin oral suspension. ASHP Drug Shortages Database. https://www.ashp.org
U.S. Food and Drug Administration. (2024). Abbreviated new drug application (ANDA) process. https://www.fda.gov
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th edition. FDA Orange Book. https://www.fda.gov
U.S. Food and Drug Administration. (2024). Generic drug facts. https://www.fda.gov

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	5
Raw Ingredient (Bulk) Api Vendors:	61
Clinical Trials:	683
Patent Applications:	1,994
DailyMed Link:	AMOXICILLIN PEDIATRIC at DailyMed

AMOXICILLIN PEDIATRIC Drug Patent Profile

When do Amoxicillin Pediatric patents expire, and what generic alternatives are available?

DrugPatentWatch^® Litigation and Generic Entry Outlook for Amoxicillin Pediatric

AI Deep Research

Questions you can ask:

Summary for AMOXICILLIN PEDIATRIC

Recent Clinical Trials for AMOXICILLIN PEDIATRIC

Pharmacology for AMOXICILLIN PEDIATRIC

US Patents and Regulatory Information for AMOXICILLIN PEDIATRIC

Amoxicillin Pediatric Market Dynamics and Financial Trajectory